Maxpro Capital Acquisition Corp. Cl A (JMAC): Price and Financial Metrics
JMAC Price/Volume Stats
| Current price | $10.81 | 52-week high | $19.22 |
| Prev. close | $11.52 | 52-week low | $7.50 |
| Day low | $10.08 | Volume | 119,000 |
| Day high | $12.72 | Avg. volume | 74,040 |
| 50-day MA | $10.60 | Dividend yield | N/A |
| 200-day MA | $10.18 | Market Cap | 145.16M |
JMAC Stock Price Chart Interactive Chart >
Maxpro Capital Acquisition Corp. Cl A (JMAC) Company Bio
Maxpro Capital Acquisition Corp. operates as a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on June 2, 2021 and is headquartered in Taipei City, Taiwan.
Latest JMAC News From Around the Web
Below are the latest news stories about MAXPRO CAPITAL ACQUISITION CORP that investors may wish to consider to help them evaluate JMAC as an investment opportunity.
Why Is Loyalty Ventures (LYLT) Stock Up 33% Today?Loyalty Ventures (LYLT) stock is taking off on Monday despite the company preparing to delist shares from the Nasdaq Exchange. |
Dear JMAC Stock Fans, Mark Your Calendars for March 20Maxpro Capital Acquisition is in the spotlight as shareholders approach a merger vote on Monday. |
Maxpro Capital Acquisition Corp. Confirms Additional Funding and Extension of Deadline to Complete Initial Business CombinationTaipei City, Jan. 13, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”) announced today that its sponsor, MP One Investment LLC (the “Sponsor”) and Apollomics Inc. (“Apollomics”), deposited additional payments in the aggregate amount of $1,035,000 (representing $0.10 per public share) (the “Extension Payment”) into the Company’s trust account for its public stockholders. This deposit enables the Company to extend the date by which the Co |
Maxpro Capital Acquisition Corp. Announces Extension to Deadline to Complete Business CombinationTAIPEI CITY, Jan. 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”), announced today that its sponsor, MP One Investment LLC (the “Sponsor”), has requested that the Company extend the date by which the Company has to consummate a business combination from January 13, 2023 to April 13, 2023 (the “Extension”). The Extension is the second of two three-month extensions permitted under the Company’s governing documents. In connection with |
Apollomics Inc. Receives FDA Orphan Drug Designation for Vebreltinib (APL-101) for Treatment of Non-Small Cell Lung Cancer with MET Genomic Tumor AberrationsFOSTER CITY, Calif., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: JMAC), an innovative biopharmaceutical company committed to the discovery and development of mono- and combination-oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to vebreltinib (APL-101) for the treatment of non-small cell lung cancer (NSCLC) with MET genomic tumor aberrations. The FDA granted the Orphan Drug Designation in August. “While NSCLC |
JMAC Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...